Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

NCT ID: NCT02947347

Last Updated: 2025-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

445 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2025-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve participants with follicular lymphoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Follicular Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(Arm A) ibrutinib + rituximab

Participants will receive 560mg of ibrutinib and rituximab 375mg/m\^2 weekly x4 with maintenance.

Group Type EXPERIMENTAL

ibrutinib

Intervention Type DRUG

ibrutinib 560mg administered orally

rituximab

Intervention Type DRUG

rituximab 375mg/m\^2 IV

(Arm B) placebo + rituximab

Participants will receive placebo and rituximab 375mg/m\^2 weekly x4 with maintenance.

Group Type PLACEBO_COMPARATOR

placebo to match ibrutinib

Intervention Type DRUG

placebo capsules to match ibrutinib administered orally

rituximab

Intervention Type DRUG

rituximab 375mg/m\^2 IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ibrutinib

ibrutinib 560mg administered orally

Intervention Type DRUG

placebo to match ibrutinib

placebo capsules to match ibrutinib administered orally

Intervention Type DRUG

rituximab

rituximab 375mg/m\^2 IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Imbruvica

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
* Measurable disease
* Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.
* Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
* Adequate hematologic function within protocol-defined parameters.
* Adequate hepatic and renal function within protocol-defined parameters.
* ECOG performance status score of 0-2.

Exclusion Criteria

* Transformed lymphoma
* Prior treatment for follicular lymphoma.
* Central nervous system lymphoma or leptomeningeal disease.
* Currently active, clinically significant cardiovascular disease.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pharmacyclics LLC.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southern Cancer Center

Mobile, Alabama, United States

Site Status

City of Hope

Duarte, California, United States

Site Status

Sansum Clinic

Santa Barbara, California, United States

Site Status

UCLA Hematology/Oncology

Santa Monica, California, United States

Site Status

Helen F. Graham Cancer Center and Research Institute

Newark, Delaware, United States

Site Status

SCRI Florida Cancer Specialists South

Fort Myers, Florida, United States

Site Status

Florida Cancer Affiliates

Ocala, Florida, United States

Site Status

SCRI Florida Cancer Specialists North

St. Petersburg, Florida, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Norton Cancer Institute

Louisville, Kentucky, United States

Site Status

Goldschmidt Cancer Center

Jefferson City, Missouri, United States

Site Status

Southeast Nebraska Cancer Center

Lincoln, Nebraska, United States

Site Status

OHSU Knight Cancer Institute Beaverton Clinic

Beaverton, Oregon, United States

Site Status

Greenville Health System

Greenville, South Carolina, United States

Site Status

SCRI Tennessee Oncology Chattanooga

Chattanooga, Tennessee, United States

Site Status

SCRI Tennessee Oncology Nashville

Nashville, Tennessee, United States

Site Status

Texas Oncology (Medical City)

Dallas, Texas, United States

Site Status

Texas Oncology-Dallas Presbyterian Hospital

Dallas, Texas, United States

Site Status

SCRI The Center For Cancer and Blood Disorders

Fort Worth, Texas, United States

Site Status

MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Texas Oncology (Tyler)

Tyler, Texas, United States

Site Status

Oncology and Hematology Associates of Southwest Virginia (Blacksburg)

Blacksburg, Virginia, United States

Site Status

Swedish Cancer Institute

Seattle, Washington, United States

Site Status

Medical Oncology Associates

Spokane, Washington, United States

Site Status

W VA University Mary Babb Randolph Cancer Center

Morgantown, West Virginia, United States

Site Status

The Canberra Hospital

Garran, Australian Capital Territory, Australia

Site Status

Mater Misericordiae Health Services

South Brisbane, Queensland, Australia

Site Status

Royal Hobart Hospital

Hobart, Tasmania, Australia

Site Status

Monash Medical Centre Clayton Campus

Clayton, Victoria, Australia

Site Status

Andrew Love Cancer Center

Geelong, Victoria, Australia

Site Status

Universitätsklinikum Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Uniklinikum Salzburg

Salzburg, , Austria

Site Status

Cliniques Universitaires Saint-Luc

Brussels, Brussels Capital, Belgium

Site Status

ZNA Stuivenberg

Antwerp, , Belgium

Site Status

AZ Sint-Jan Brugge Oostende AV

Bruges, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

CHU de Liège

Liège, , Belgium

Site Status

AZ Nikolaas

Sint-Niklaas, , Belgium

Site Status

Gasthuis Zusters Antwerpen

Wilrijk, , Belgium

Site Status

Moncton Hospital

Moncton, New Brunswick, Canada

Site Status

CHUM Notre Dame Hospital

Montreal, Quebec, Canada

Site Status

CIUSSS-de-l'Est-de-l'Île-de-Montréal

Montreal, Quebec, Canada

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice Ostrava

Ostrava, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady

Prague, , Czechia

Site Status

Fakultni nemocnice v Motole

Prague, , Czechia

Site Status

Centre Hospitalier de Valence

Valence, Drôme, France

Site Status

CHRU de Poitiers La Miletrie

Poitiers, Vienne, France

Site Status

CHU de Limoges Hôpital Dupuytren

Limoges, , France

Site Status

CHU Bordeaux

Pessac, , France

Site Status

Centre Hospitalier de Perigueux

Périgueux, , France

Site Status

Hôpital Civil

Strasbourg, , France

Site Status

University General Hospital of Patras

Pátrai, Achaïa, Greece

Site Status

Laiko General Hospital of Athens

Athens, Attica, Greece

Site Status

University General Hospital of Larissa

Larissa, , Greece

Site Status

Somogy Megyei Kaposi Mór Oktató Kórház

Kaposvár, Somogy County, Hungary

Site Status

Országos Onkológiai Intézet

Budapest, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont

Debrecen, , Hungary

Site Status

Petz Aladár Megyei Oktató Kórház

Győr, , Hungary

Site Status

Pécsi Tudományegyetem

Pécs, , Hungary

Site Status

Barzilai Medical Center

Ashkelon, , Israel

Site Status

Bnei Zion Medical Center

Haifa, , Israel

Site Status

Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status

Rabin Medical Center Beilinson Campus

Petah Tikva, , Israel

Site Status

Assuta Medical Center

Tel Aviv, , Israel

Site Status

Assaf Harofe Medical Center

Ẕerifin, , Israel

Site Status

Ospedale Infermi di Rimini

Rimini, Emilia-Romagna, Italy

Site Status

Ospedale Policlinico San Martino

Genoa, Liguria, Italy

Site Status

Istituto Europeo Di Oncologia

Milan, Lombardy, Italy

Site Status

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Turin, Piedmont, Italy

Site Status

Azienda ospedaliera Universiataria Senese

Siena, Tuscany, Italy

Site Status

Centro Di Riferimento Oncologico

Aviano, , Italy

Site Status

Azienda Sanitaria Ospedaliera S. Croce e Carle

Cuneo, , Italy

Site Status

Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST

Meldola, , Italy

Site Status

San Raffaele Scientific Institute

Milan, , Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda

Milan, , Italy

Site Status

Azienda Ospedaliero Universitaria di Parma

Parma, , Italy

Site Status

Farmacia Polo Ematologico Policlinico Umberto I

Roma, , Italy

Site Status

Policlinico Universitario Campus Biomedico di Roma

Roma, , Italy

Site Status

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Torino, , Italy

Site Status

Gelre Ziekenhuizen

Apeldoorn, Gelderland, Netherlands

Site Status

Maasstad Ziekenhuis

Rotterdam, South Holland, Netherlands

Site Status

Leids Universitair Medisch Centrum

Leiden, , Netherlands

Site Status

ETZ-Elisabeth

Tilburg, , Netherlands

Site Status

Centrum Onkologii Ziemi Lubelskiej

Lublin, Lublin Voivodeship, Poland

Site Status

Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Szpitale Pomorskie Sp. z o. o.

Gdynia, Pomeranian Voivodeship, Poland

Site Status

Malopolskie Centrum Medyczne

Krakow, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu

Wroclaw, , Poland

Site Status

Unidade Local de Saúde de Matosinhos SA

Matosinhos Municipality, , Portugal

Site Status

Centro Hospitalar de São João, E.P.E.

Porto, , Portugal

Site Status

Centro Hospitalar do Porto - Hospital de Santo António

Porto, , Portugal

Site Status

Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe

Porto, , Portugal

Site Status

Regional Clinical Hospital

Krasnoyarsk, , Russia

Site Status

Russian Oncology Research Center n a N N Blokhin

Moscow, , Russia

Site Status

Nizhegorodskaya Regional Clinical Hospital n.a. Semashko

Nizhny Novgorod, , Russia

Site Status

City Hospital #31

Saint Petersburg, , Russia

Site Status

North-West Federal Medical Research Center n.a. V.A. Almazov

Saint Petersburg, , Russia

Site Status

Hospital de Cabueñes

Gijón, Principality of Asturias, Spain

Site Status

Hospital Universitario Virgen de Valme

Seville, Sevilla, Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital Universitario Germans Trias i Pujol

Barcelona, , Spain

Site Status

Hospital Vall dHebron

Barcelona, , Spain

Site Status

ICO L'Hospitalet

Barcelona, , Spain

Site Status

Hospital Universitario HM Sanchinarro - CIOCC

Madrid, , Spain

Site Status

Hospital Universitario Infanta Leonor

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Arnau de Vilanova

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valladolid

Valladolid, , Spain

Site Status

Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Kaohsiung Medical University Hospital

Kaohsiung City, , Taiwan

Site Status

Chi Mei Medical Center, Liouying

Liuying, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Gazi Universitesi Tip Fakultesi Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Ege Universitesi Tip Fakultesi Hastanesi

Bornova, , Turkey (Türkiye)

Site Status

Mersin Universitesi Tip Fakultesi Hastanesi

Gaziantep, , Turkey (Türkiye)

Site Status

Erciyes Universitesi Tip Fakultesi Hastanesi

Kayseri, , Turkey (Türkiye)

Site Status

Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi

Kocaeli, , Turkey (Türkiye)

Site Status

Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi

Samsun, , Turkey (Türkiye)

Site Status

Namik Kemal Universitesi Tip Fakultesi Hastanesi

Tekirdağ, , Turkey (Türkiye)

Site Status

Royal Cornwall Hospital - Hospital Treliske

Tururo, Cornwall, United Kingdom

Site Status

Norfolk and Norwich University Hospital

Norwich, Norfolk, United Kingdom

Site Status

Addenbrooke's Hospital

Cambridge, , United Kingdom

Site Status

Leeds Teaching Hospitals NHS Trust

Leeds, , United Kingdom

Site Status

Barts and The London NHS Trust

London, , United Kingdom

Site Status

Derriford Hospital

Plymouth, , United Kingdom

Site Status

Royal Berkshire Hospital NHS Foundation Trust

Reading, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Czechia France Greece Hungary Israel Italy Netherlands Poland Portugal Russia Spain Taiwan Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-003202-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PCYC-1141-CA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.